C

oncerned about the way that some drug makers report earnings in their financial statements, the US Securities and Exchange Commission recently indicated plans to evaluate pharmaceutical industry accounting practices.

The plans were disclosed in a Jan. 11 letter that the agency sent to Allergan over GAAP, or generally accepted accounting principles. Specifically, the SEC expressed reservations about the use of so-called non-GAAP to report earnings per share and maintained that, while other companies “make these types of significant adjustments, it does not suggest that the magnitude of your departure from GAAP results … is at all common.” The letter was first reported by the Wall Street Journal.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X